Real-world outcome in the pre-car-t era of myeloma patients qualifying for car-t cell therapy
Conclusion:Myeloma patients refractory after at least three lines of anti-CD38/PI/IMID treatment have a poor prognosis with a PFS of 6.6 months and OS of 13.5 months. These data may serve as reference to compare the potential benefit of CAR-T treatment in this group of myeloma patients when available in the near future.
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Authors: Ulrike Bacher, Simon Brechb ühl, Barbara Jeker, Thomas Pabst Source Type: research
More News: Dexamethasone | Hematology | Infectious Diseases | Myeloma | Revlimid | Stem Cell Therapy | Stem Cells | Study | Switzerland Health | Transplants | Velcade